|
|
|||
|
||||
OverviewThis book examines and evaluates the strategies utilized to design and synthesize pharmaceutically active agents. Significant updates over the last 10 years since the publication of the 1st edition include synthesis of enantiomerically pure isomers, novel chemical methodologies, and new pharmaceutical agents targeted at novel biological endpoints. Written by an experienced successful author, this book meets the needs of a growing community of researchers in pharmaceutical R &D, as well as medical professionals, by providing a useful guide for designing and synthesizing pharmaceutical agents. Additionally, it is a useful text for medicinal chemistry students. Full Product DetailsAuthor: Daniel Lednicer (Analytical Bio-Chemistry Laboratories, Inc., Columbia, Missouri)Publisher: John Wiley & Sons Inc Imprint: Wiley-Interscience Edition: 2nd edition Dimensions: Width: 16.30cm , Height: 3.80cm , Length: 23.60cm Weight: 1.089kg ISBN: 9780470190395ISBN 10: 0470190396 Pages: 700 Publication Date: 14 November 2008 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Out of stock The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsReviewsA In this book, Lednicer presents a detailed discussion of strategies toward the synthesis of pharmaceutical compounds... The strength of the book is the wealth of data collected in one relatively short toneA . In this book, Lednicer presents a detailed discussion of strategies toward the synthesis of pharmaceutical compounds... The strength of the book is the wealth of data collected in one relatively short tone . ?In this book, Lednicer presents a detailed discussion of strategies toward the synthesis of pharmaceutical compounds. . . The strength of the book is the wealth of data collected in one relatively short tone?. Author InformationDaniel Lednicer, PhD, is the acclaimed author of several books on drug synthesis and discovery. His career has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. He has also served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute. Tab Content 6Author Website:Countries AvailableAll regions |
||||